Compare Eli Lilly And Co (LLY) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Schlumberger NV — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Schlumberger NV trades at $48.85 (market cap $72.69B). The key difference: Eli Lilly And Co is far larger — about 14.3× Schlumberger NV's market cap, and Schlumberger NV pays the higher dividend (2.41%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Schlumberger NV for 99 Days on average.
| LLY | SLB | |
|---|---|---|
Market Cap | $1.04T | $72.69B |
Volume | 3,064,878 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $1.28K | $60.10 |
52-Week Low | $799.57 | $31.72 |
Typical Hold Time | 93 Days | 99 Days |
Enterprise Value | $1.09T | $81.42B |
Dividend Yield | 0.59% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
SLB trades at $48.91, up 1.98% today, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 8.53% net margin and 13.37% ROE, supported by recent contract wins in Saudi Arabia and Mozambique. Revenue declined slightly to $35.71B in 2025, but operating cash flow remains robust at $6.49B. Analyst consensus is strongly bullish with 85% buy ratings and $64.58 price target, representing 32% upside potential.
SLB presents a compelling value opportunity with strong fundamentals and positive analyst sentiment, though technical indicators suggest near-term weakness. The stock's current valuation at 23.89 P/E appears reasonable given the company's contract momentum and global energy technology leadership. Key risks include energy price volatility and execution challenges in new projects, but the dividend yield and institutional support provide downside protection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
